Michael Farrell - Zimmer Biomet Independent Director
| ZBH Stock | USD 119.33 1.97 1.62% |
Director
Mr. Michael J. Farrell is Independent Director of Zimmer Biomet Holdings, Inc. Chief Executive Officer of ResMed Inc. since March 2013. Prior to that appointment, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Genzyme Corporationrationration, The Dow Chemical Company and BHP Billiton. Mr. Farrell holds a bachelor of engineering, with firstclass honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management. Michael J. Farrells service as CEO of ResMed Inc., a global leader in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, provides him with significant experience leading a highly regulated, global medical device company. Mr. Farrell is spearheading the companys expansion into emerging markets and its investments in connected health and digital health, major growth initiatives for ResMed that fit well with our own plans for global growth. In his prior roles, Mr. Farrell led ResMeds MA and alliance creation activities, as well as the marketing function. In addition, during his tenure with ResMed, Mr. Farrell has gained domestic and international PL experience, first as head of the companys major global business unit, and then as President, Americas since 2014.
| Age | 48 |
| Tenure | 10 years |
| Address | 345 East Main Street, Warsaw, IN, United States, 46580 |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Michael Farrell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Farrell against Zimmer Biomet stock is an integral part of due diligence when investing in Zimmer Biomet. Michael Farrell insider activity provides valuable insight into whether Zimmer Biomet is net buyers or sellers over its current business cycle. Note, Zimmer Biomet insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zimmer Biomet'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Farrell few days ago Acquisition by Michael Farrell of 55468 shares of ResMed at 148.9 subject to Rule 16b-3 |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.18, while Return On Capital Employed is projected to decrease to 0.07. As of now, Zimmer Biomet's Fixed Asset Turnover is decreasing as compared to previous years. The Zimmer Biomet's current Asset Turnover is estimated to increase to 0.68, while Total Assets are projected to decrease to under 13.7 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| William Miller | Waters | 70 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Rebecca Chambers | Illumina | N/A | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Robert Epstein | Illumina | 62 | |
| Bahija Jallal | Guardant Health | 56 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| Michael Berendt | Waters | 71 | |
| George Milne | Charles River Laboratories | 77 | |
| Richard Reese | Charles River Laboratories | 75 | |
| George Llado | Charles River Laboratories | 55 | |
| Martin Harris | Thermo Fisher Scientific | 61 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Thomas Salice | Waters | 61 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Christopher Kuebler | Waters | 66 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Hans Maerki | Mettler Toledo International | 71 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
Management Performance
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Coleman Lannum, Senior Vice President - Investor Relations | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Matt Abernethy, CPA, Vice President Investor Relations | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Daniel Florin, CFO, Senior Vice President | ||
| Robert Marshall, Vice President - Investor Relations, Treasurer | ||
| David Nolan, Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing | ||
| Joseph Cucolo, President Americas | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Cecil Pickett, Independent Director | ||
| Angela Main, Global VP | ||
| Aure Bruneau, Group President Spine, CMF, Thoracic and Surgery Assisting Technology | ||
| Jeffrey Rhodes, Director | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Katarzyna MazurHofsaess, President Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Paul Bisaro, Independent Director | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Adam Johnson, Group President Spine, Dental, CMF and Thoracic | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Daniel Williamson, Group President Joint Reconstruction | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| David Dvorak, CEO and President and Director | ||
| Michael Farrell, Independent Director | ||
| Tony Collins, Chief Accounting Officer, Vice President Controller | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| Gail Boudreaux, Independent Director | ||
| Stuart Kleopfer, President Americas | ||
| Robert Hagemann, Independent Director | ||
| Robert Delps, President Americas |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0836 | ||||
| Return On Asset | 0.044 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 30.68 B | ||||
| Shares Outstanding | 205.46 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 90.97 % | ||||
| Number Of Shares Shorted | 4.73 M | ||||
| Price To Earning | 77.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.96 | Earnings Share 4.88 | Revenue Per Share 35.43 | Quarterly Revenue Growth 0.063 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.